AD/PD 2026: Roche’s prasinezumab shows promise on PD progression with five-year data

At AD/PD 2026, Roche announced that patients treated with prasinezumab for five years demonstrated a sustained slowing of ...
manilatimes

Kazia Therapeutics Announces Compelling Preclinical and Translational Data for Nuclear PD-L1 Degrader (NDL2)

SYDNEY, Jan. 30, 2026 /PRNewswire/ -- Kazia Therapeutics (NASDAQ: KZIA), an oncology-focused pharmaceutical company developing novel therapies for difficult-to-treat cancers, today announced ...

AD/PD 2026: Three-year data confirms slow amyloid re-accumulation following Kisunla treatment completion

On 20 March, at the AD/PD 2026 International Conference on Alzheimer’s and Parkinson’s Diseases and Related Neurological ...
PharmiWeb

Cantargia Announces Successful Phase 1 Results: PK/PD Data of Subcutaneously Administered CAN10 Confirms Every 4-Week Dosing Choice in Phase 2

Pharmacokinetic (PK) model generated based on the single ascending dose (SAD) data and the first multiple ascending dose (MAD) cohort. Model confirms the predicted dosing regimen for phase 2, ...
Yahoo Finance

2025 ASCO Oral Presentation: Innovent Biologics Announces Updated Data of IBI363 (First-in-class PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) from the Phase 1 PoC ...

SAN FRANCISCO and SUZHOU, China, June 3, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and ...
Investing

Kazia reports promising data for nuclear PD-L1 degrader NDL2

SYDNEY - Kazia Therapeutics (NASDAQ:KZIA) unveiled preclinical and translational data for NDL2, a protein degrader designed to eliminate nuclear PD-L1, which the company identifies as a driver of ...